Introduction {#s1}
============

Proper specification of the trachea and esophagus is critical for the function of the respiratory and digestive systems. Formation of the trachea and esophagus requires signals from the splanchnic mesenchyme which specify ventral and dorsal domains of the foregut endoderm tube, resulting in lung bud outgrowth and the initiation of physical separation of the trachea and esophagus ([@bib2]; [@bib3]; [@bib4]; [@bib7]; [@bib9]; [@bib31]; [@bib43]; [@bib42]; [@bib47]; [@bib54]). Ultimately, the tracheal epithelium is composed of multi-ciliated, secretory, and basal cells within a pseudostratified columnar monolayer which is surrounded by mesenchyme-derived ventral cartilaginous rings, and dorsal smooth muscle of the trachealis. The esophagus consists ultimately of a stratified squamous keratinized epithelium surrounded by smooth muscle. Early failure of tracheoesophageal (TE) fate specification can result in an unseparated common foregut endoderm tube, producing common congenital pathologies known as tracheoesophageal fistula (TEF) or tracheal agenesis (TA) ([@bib2]; [@bib32]; [@bib48]). Other anomalies of foregut development, such as tracheomalacia and congenital tracheal stenosis, involve the improper formation of the adjacent tracheal mesenchyme-derived cartilage and smooth muscle ([@bib32]; [@bib48]). While foregut malformations in humans are common, we know very little of the genetic causes of these defects, in part due to a paucity of information of normal tracheoesophageal transcriptional patterning.

The earliest marker of tracheal and lung fate is the transcription factor NKX2-1 (TTF1) which is expressed in the ventral foregut in a pattern complementary to the dorsally enriched expression of the transcription factor SOX2 ([@bib8]; [@bib29]; [@bib30]; [@bib40]). Disruption of *Nkx2-1* in mice resulted in upregulation of SOX2 in the ventral endoderm and differentiation of the adjacent mesenchyme into smooth muscle rather than tracheal cartilage ([@bib29]; [@bib40]). Conversely, hypomorphic disruption of *Sox2* in mice resulted in upregulation of dorsal NKX2-1 and a conversion of the stratified esophageal epithelium to a simple columnar epithelium surrounded by smooth muscle that histologically resembles that of the trachea ([@bib40]; [@bib57]). Similarly, knockdown of SOX2 in human induced pluripotent stem cell (hiPSC)-derived dorsal foregut cells resulted in upregulation of NKX2-1, and forced expression of SOX2 in hiPSC-derived ventral foregut cells repressed NKX2-1 ([@bib58]). Together these data have given rise to a model in which NKX2-1 and SOX2 form a co-repressive master regulatory switch to define tracheal and esophageal cell fates ([@bib2]; [@bib4]; [@bib40]; [@bib57]; [@bib58]). The regulatory programs downstream of NKX2-1 and SOX2 are not known and, therefore, the extent to which each promotes or represses tracheal and esophageal cell fates is not clear. Moreover, beyond these two transcription factors, we currently know very little about the transcriptional identity of the early dorsoventral endodermal populations that ultimately give rise to the trachea and esophagus.

The mechanisms coupling epithelial and mesenchymal fate specification in the trachea and esophagus are not well understood, but involve epithelial to mesenchymal signaling. For example, loss of WNT signaling from the endoderm to the tracheal mesenchyme results in a loss of tracheal cartilage and a corresponding expansion of smooth muscle ([@bib12]; [@bib16]; [@bib50]). SHH signaling regulates smooth muscle specification in multiple contexts ([@bib13]; [@bib25]) and loss of SHH signaling from the airway and intestinal epithelium results in loss of smooth muscle formation ([@bib14]; [@bib22]; [@bib37]) and mispatterning of tracheal cartilage ([@bib28]; [@bib45]). Thus, while WNT and SHH signaling are critical for foregut mesenchymal differentiation, how these signals are transcriptionally regulated in the tracheal and esophageal epithelium is currently unknown.

In this study, we dissect the transcriptional regulation of tracheal and esophageal fate specification by combining multiple genomic approaches. By single cell RNA-sequencing (scRNA-seq) we define the transcriptional identity of the trachea, esophagus, and lung at their initial stages of development, and identify new and robust markers of tracheoesophageal specification. We then dissect the NKX2-1 regulatory program that specifies TE identity using our scRNA-seq datasets, in combination with bulk RNA-sequencing of *Nkx2-1^-/-^* mutant tracheas, and NKX2-1 chromatin immunoprecipitation and sequencing (ChIP-seq) of wild type tracheas. We discover a previously unknown NKX2-1-independent transcriptional program that encompasses the majority of the newly-identified tracheal and esophageal transcriptomes. We assay the NKX2-1 transcriptional program in functional compound mouse mutant experiments to test whether NKX2-1 regulates these TE genes through repression of SOX2 or independently of SOX2. These data uncover a role for NKX2-1 in regulating epithelial-to-mesenchymal signaling, thereby coupling TE epithelial identity with cartilage and smooth muscle fate specification. This study therefore establishes a new framework for understanding key regulators of early cell fate specification in the trachea and esophagus.

Results {#s2}
=======

Single cell transcriptomics identifies dorsoventral populations of the foregut {#s2-1}
------------------------------------------------------------------------------

To understand how the trachea and esophagus are specified on a transcriptome-wide scale, we performed droplet-based single-cell RNA sequencing (scRNA-seq) on E10.5 mid-separation and E11.5 post-separation dissected mouse foregut epithelial cells. We generated 6407 single-cell transcriptomes at E10.5, comprising 5 cell clusters, and 10,493 single-cell transcriptomes at E11.5, comprising 7 cell clusters, and visualized these clusters using Uniform Manifold Approximation and Projection (UMAP) dimensional reduction ([@bib1]; [@bib55]; [Figure 1a,b](#fig1){ref-type="fig"}). We delineated the dorsoventral axis in our scRNA-seq data at E10.5 and E11.5 by projecting the expression levels of *Nkx2-1* and *Sox2* on the UMAP ([Figure 1---figure supplement 1c,d](#fig1s1){ref-type="fig"}). Similarly, *Sox9*, a marker of developing lung epithelium ([@bib11]; [@bib39]; [@bib44]), marked a subset of *Nkx2-1*-positive respiratory cells, enabling us to distinguish distal lung from trachea ([Figure 1---figure supplement 1c,d](#fig1s1){ref-type="fig"}). Using differential expression analysis for each cell cluster and RNAscope fluorescent in-situ hybridization, we defined cell clusters as lung, trachea, esophagus, and pharynx ([Figure 1a--l''](#fig1){ref-type="fig"}, [Figure 1---figure supplement 2a--m](#fig1s2){ref-type="fig"}, [Figure 1---figure supplement 3a--c](#fig1s3){ref-type="fig"}, [Figure 1---figure supplement 4a](#fig1s4){ref-type="fig"}) as well as a cluster corresponding to the ultimobranchial body, a derivative of the pharyngeal endoderm that gives rise to the follicular cells of the thyroid ([@bib34]; [Figure 1---figure supplement 4b](#fig1s4){ref-type="fig"}). Within the E11.5 lung, we identified a cluster with unique expression of known distal lung markers such as *Bmp4* ([@bib60]; [Figure 1---figure supplement 3c](#fig1s3){ref-type="fig"}, [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}), demonstrating that the proximodistal lung axis can be identified by markers in our dataset. Signatures of proliferation also divided both the trachea and lung clusters at E11.5 ([Figure 1b](#fig1){ref-type="fig"}, [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}).

![Single-cell transcriptomics of the developing foregut epithelium identifies distinct dorsoventral populations.\
Dissected, FACS-purified foregut epithelial cells were subjected to droplet-based single-cell RNA sequencing at E10.5 and E11.5. (**a**) UMAP representation of 6,407 cells identified at E10.5 and (**b**) 10,493 cells identified at E11.5. Colors represent cell populations identified using shared nearest neighbor clustering. vFG: ventral foregut, dFG: dorsal foregut, Ph: pharynx, UBB: ultimobranchial body, Tr: trachea, Es: esophagus. (**c**) Heatmap of selected marker gene expression across 100 E10.5 cells each of ventral foregut/trachea, lung, and esophagus/dorsal foregut as identified by scRNA-seq. Selected genes are markers of respiratory, lung, ventral FG/trachea, and dorsal FG/esophagus cells (top to bottom). n = 1 biological replicate/timepoint with 20 pooled embryos at E10.5 and 28 pooled embryos at E11.5. See also: [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}. (**d-l**) RNA localization of pan-respiratory marker gene *Irx2*, ventral FG/trachea marker gene *Tppp3*, and dorsal FG/esophagus marker gene *Krt19* identified from differential expression analysis of cell populations in scRNA-seq data at E10.5. First column shows projection of RNA expression level as determined by scRNA-seq on UMAP. Second-fourth columns show RNA expression of marker gene (green) and NKX2-1 expression (magenta) in the undivided region of E10.5 embryonic foreguts (I) as indicated by the positions of the schematic in a). Last two columns show staining in the lung and distal esophagus (II) as indicated by the positions of the schematic in **a**). All images were captured at 20X magnification and displayed at the same scale. Scale bar = 50 um.\
Figure 1---source data 1.Top 20 markers of foregut cell populations identified by scRNA-seq of E10.5 and E11.5 foreguts.](elife-55526-fig1){#fig1}

Our scRNA-seq data revealed a wealth of genes previously unknown to mark cell types of the ventral and dorsal foregut prior to TE separation ([Figure 1c](#fig1){ref-type="fig"}, [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}), as well as new genes that distinguish the trachea, lung, and esophagus after TE separation ([Figure 1---figure supplement 3c](#fig1s3){ref-type="fig"}, [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}). To visualize their spatial expression, we performed RNAscope for several genes marking each of these cell types in the undivided E10.5 foregut and lung ([Figure 1d--l](#fig1){ref-type="fig"}; [Figure 1---figure supplement 2a--m](#fig1s2){ref-type="fig"}), and the E11.5 trachea, esophagus, and lung ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). In all cases, RNAscope analysis confirmed our scRNA-seq finding and provided additional information about the spatial patterns of marker gene expression. We found many genes, including *Klf5*, *Krt19*, *Dcn*, *Pitx1*, and *Lrig1* that exhibited expression specifically within the dorsal foregut/esophageal cells ([Figure 1c,j--l''](#fig1){ref-type="fig"}; [Figure 1---figure supplement 2k--m"](#fig1s2){ref-type="fig"}, [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}, [Figure 3---figure supplement 1b](#fig3s1){ref-type="fig"}). Interestingly, within the foregut endoderm, all of these genes were more dorsally restricted than SOX2 and were more precisely complementary to NKX2-1, indicating that they may serve as better markers of the esophagus during its early development ([Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}). Notably, we also discovered genes such as *Tppp3*, *Pcdh10*, *Ly6h*, and *Cldn18* that exhibited enrichment in the ventral foregut at E10.5 ([Figure 1c,g--i"](#fig1){ref-type="fig"}, [Figure 1---figure supplement 2e-j\'](#fig1s2){ref-type="fig"}) and specifically marked the trachea and proximal airway at E11.5 ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). Our discovery of this gene class indicates that the trachea and proximal airway are actively transcriptionally specified and at least somewhat distinct from the lung during early respiratory development. All tracheal and esophageal markers we identified and validated were dorsoventrally restricted in the common foregut of E10.5 embryos prior to physical separation of the trachea and esophagus, consistent with extensive fate specification before TE separation ([@bib2]). Together, these data uncover a multitude of previously unknown genes that define initial dorsoventral patterning of the foregut and the earliest stages of the trachea, lung, and esophagus.

Identification of the NKX2-1 transcriptional program and an independent program of TE specification {#s2-2}
---------------------------------------------------------------------------------------------------

Given our discovery of a broad network of previously unknown genes expressed during early TE specification, we sought to examine how tracheoesophageal fates are dysregulated upon *Nkx2-1* loss at the transcriptome-wide scale. We performed RNA-sequencing (RNA-seq) of dissected and FACS-purified foregut epithelium from E11.5 *Nkx2-1^-/-^* and wild-type (WT) embryos. Differential expression analysis between *Nkx2-1*^-/-^ and WT foregut epithelium identified 257 NKX2-1-dependent genes, with 109 genes upregulated and 148 genes downregulated in *Nkx2-1^-/-^* foreguts ([Figure 2a](#fig2){ref-type="fig"}, [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). We examined the expression of these NKX2-1-dependent genes in our scRNA-seq dataset at E11.5 to determine, on a global-scale, where they were expressed in the developing foregut. We found that genes that were upregulated in *Nkx2-1^-/-^* mutants were enriched in cells of the esophagus and pharynx ([Figure 2b](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1a](#fig2s1){ref-type="fig"}), and genes that were downregulated in *Nkx2-1^-/-^* mutants were enriched in tracheal and lung cells ([Figure 2c](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1b](#fig2s1){ref-type="fig"}). Together, these data define the NKX2-1 transcriptional program in early TE development and support the hypothesis that, within this program, NKX2-1 positively regulates tracheal genes and negatively regulates esophageal genes.

![Transcriptomic analysis of *Nkx2-1^-/-^* foreguts reveals NKX2-1 regulated tracheal and esophageal transcriptional programs.\
(**a**) Dissected, FACS-purified epithelium from E11.5 *Nkx2-1^-/-^* and WT foreguts was sequenced and analyzed for differential gene expression. 109 genes were increased and 148 genes were decreased in *Nkx2-1^-/-^* foreguts compared to WT (DESeq2, log2FC \> 0.7, padj \< 0.05). Labeled genes show examples of tracheal genes that decrease in *Nkx2-1^-/-^* mutants (*Tppp3, Pcdh10, Wnt7b, Nkx2-1*), and esophageal genes that increase in *Nkx2-1^-/-^* mutants (*Klf5, Has2, Shh*). n = 3 biological replicates with two pooled embryos/replicate. See also: [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}. (**b-c**) Combined expression of all genes that increase (**b**) or decrease (**c**) in *Nkx2-1^-/-^* foreguts as a percentage of all reads in E11.5 scRNA-seq data. Cells are grouped by their assigned cluster and clusters were subsampled to 600 cells/cluster for visualization.\
Figure 2---source data 1.Differentially expressed genes between E11.5 *Nkx2-1^-/-^* and WT foregut epithelium identified with bulk RNA-seq.](elife-55526-fig2){#fig2}

Surprisingly, our scRNA-seq dataset identified many genes that mark tracheal and esophageal cells that did not appear to exhibit a change in expression in our *Nkx2-1^-/-^* mutant RNA-seq analysis ([Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}, [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). We examined the spatial expression of several of these NKX2-1-independent genes using an *Nkx2.5-cre* strain which mediates recombination in the ventral foregut ([Figure 3---figure supplement 1a](#fig3s1){ref-type="fig"}; [@bib52]) to generate *Nkx2-1^lox/lox^; Nkx2.5^cre/+^* (Nkx2-1-TrKO) embryos lacking NKX2-1 in the trachea. All Nkx2-1-TrKO embryos we examined exhibited a complete failure of foregut separation (n = 8/8 embryos). Using RNAscope, we found *Irx2*, *Ly6h*, and *Nrp2* to be tracheal-specific and maintained in the ventral epithelium of the unseparated foregut tube in E11.5 Nkx2-1-TrKO embryos ([Figure 3a--f'](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1b](#fig3s1){ref-type="fig"}). Likewise, we found *Dcn*, *Ackr3*, and *Meis2* to be esophageal-specific and maintained in the dorsal region of the common foregut tube in Nkx2-1-TrKO foreguts ([Figure 3g--l'](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1b](#fig3s1){ref-type="fig"}). Immunofluorescent staining also showed that the esophageal genes LRIG1 and PITX1 were maintained in the dorsal region of *Nkx2-1^-/-^* foreguts ([Figure 3---figure supplement 1b](#fig3s1){ref-type="fig"}). These data indicate the presence of an NKX2-1-independent transcriptional program within the developing trachea and esophagus, and suggest that *Nkx2-1^-/-^* mutant foreguts do not undergo a complete tracheal-to-esophageal fate conversion.

![Identification of an NKX2-1-independent tracheal and esophageal program.\
(**a-l**) RNA localization of NKX2-1-independent tracheal (*Irx2, Ly6h*) and esophageal (*Dcn, Ackr3*) makers identified by scRNA-seq and *Nkx2-1^-^*^*/*-^ mutant RNA-seq data at E11.5. First column shows projection of RNA expression level as determined by scRNA-seq on UMAP. Second-fifth columns show RNA localization (green) in E11.5 control and Nkx2-1-TrKO embryos with immunofluorescent staining of NKX2-1 (magenta) and SOX2 (cyan). 8/8 Nkx2-1-TrKO embryos had TEF phenotype, n = 3 embryos/staining combination. All images were captured at 20X magnification and displayed at the same scale. Scale bar = 50 um. (**m**) Schematic of experimental procedures for RNA-seq and differential expression analysis of WT trachea and esophagus for comparison with *Nkx2-1^-/-^* mutant RNA-seq data. n = 3 biological replicates with four pooled embryos/replicate. See also: [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}. (**n**). NKX2-1-dependent genes as a portion of genes enriched in WT trachea (left) and esophagus (right). NKX2-1-independent genes make up 89% of tracheal-enriched genes and 94% of esophageal enriched genes.\
Figure 3---source data 1.Differentially expressed genes between E11.5 WT trachea and esophagus epithelium identified with bulk RNA-seq.](elife-55526-fig3){#fig3}

We therefore examined the extent to which tracheoesophageal patterning is independent of NKX2-1 by generating bulk transcriptional profiles of WT tracheal and esophageal epithelium at E11.5 to compare with our *Nkx2-1^-/-^* mutant bulk RNA-seq dataset ([Figure 3m](#fig3){ref-type="fig"}). Differential expression analysis identified 1126 genes enriched in the trachea and 809 genes enriched in the esophagus of WT embryos ([Figure 3n](#fig3){ref-type="fig"}, [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}). Notably, only 11% of tracheal-enriched genes and 6% of esophageal-enriched genes in WT foreguts were affected by loss of NKX2-1, and the majority of tracheal- or esophageal-enriched genes were unchanged in *Nkx2-1^-/-^* foreguts ([Figure 3n](#fig3){ref-type="fig"}). Together, these findings define relevant NKX2-1 transcriptional targets during early tracheoesophageal development and uncover a significant NKX2-1-independent gene regulatory program.

NKX2-1 directly regulates foregut genes, with variable dependency on SOX2 {#s2-3}
-------------------------------------------------------------------------

To identify direct targets of NKX2-1 during TE specification, we performed NKX2-1 chromatin immunoprecipitation followed by sequencing (ChIP-seq) on dissected E11.5 WT trachea. We identified 15,861 genomic regions (peaks) shared between two biological replicates that showed NKX2-1 binding ([Figure 4a](#fig4){ref-type="fig"}, FDR \< 0.00001) and were centrally enriched for the known NKX2-1 motif ([Figure 4b](#fig4){ref-type="fig"}, p=3.4e-37). We next looked closely at NKX2-1 binding at or near the loci of select NKX2-1-dependent tracheal and esophageal genes. We observed NKX2-1 binding at the *Nkx2-1* promoter and five binding sites within 10 kb of the *Nkx2-1* gene, consistent with previous data suggesting that NKX2-1 autoregulates its own expression ([@bib33]; [@bib35]; [@bib56]), and also observed binding of NKX2-1 at the *Sox2* promoter and four binding sites within the *Sox2* locus, suggesting direct repression of *Sox2* by NKX2-1 ([Figure 4c](#fig4){ref-type="fig"}). In addition, NKX2-1 binding was observed at the promoter of genes such as *Pcdh10, Tppp3,* and *Klf5* that we identified as specific markers of the tracheal and esophageal lineages by scRNA-seq ([Figure 4c](#fig4){ref-type="fig"}), suggesting that these genes may also be direct targets of NKX2-1 regulation. Genome-wide comparison of NKX2-1-bound genes with the *Nkx2-1^-/-^* de-regulated transcriptome revealed that NKX2-1-dependent genes were associated with NKX2-1 ChIP-seq peaks at a higher frequency than observed at random ([Figure 4d](#fig4){ref-type="fig"}, Fisher's exact test, p\<0.0001). Furthermore, when we divided NKX2-1-dependent genes into those that were upregulated or downregulated in *Nkx2-1^-/-^* mutants, we found that genes that are downregulated in *Nkx2-1^-/-^* mutants are more frequently associated with NKX2-1 ChIP-seq peaks ([Figure 4d](#fig4){ref-type="fig"}, Fisher's exact test, p\<0.0001). These data suggest that whereas NKX2-1 is a direct positive regulator of tracheal-specific genes, repression of esophageal-specific genes may more often be indirect.

![NKX2-1 binds directly to tracheoesophageal genes in the developing foregut.\
(**a**) ChIP-seq for NKX2-1 in E11.5 foreguts identified 15,861 NKX2-1-bound genomic regions (peaks) shared between replicates (FDR \< 0.00001). n = 2 biological replicates with 175 pooled embryos/replicate. (**b**) Motif analysis of NKX2-1 ChIP-seq data shows peaks are enriched for the NKX2-1 motif (p=3.4e-37). (**c**) NKX2-1 ChIP-seq (black) and input (grey) tracks near loci of select NKX2-1-dependent genes (blue) *Nkx2-1, Sox2, Pcdh10, Tppp3,* and *Klf5* visualized in IGV. Input and NKX2-1 IP tracks are displayed at the same linear scale, as indicated by IGV Data Range on the y-axis. Horizontal scale bar = 10 kb. (**d**) Genome-wide comparison of NKX2-1 ChIP-seq with *Nkx2-1^-/-^* mutant RNA-seq. Overlap of NKX2-1 ChIP-seq associated genes with NKX2-1-dependent genes (top), genes increased in *Nkx2-1^-/-^* mutants (middle) and genes decreased in *Nkx2-1^-/-^* mutants (lower). \*asterisk = p \< 0.0001, Fisher's exact test.](elife-55526-fig4){#fig4}

Based on previous studies, NKX2-1 indirect regulation may be mediated through its repression of *Sox2* ([@bib2]). Indeed, given the well-established genetically co-repressive relationship of SOX2 and NKX2-1 in the foregut ([@bib4]; [@bib40]; [@bib57]; [@bib58]), it is challenging to determine whether the transcriptional changes we observed in *Nkx2-1^-/-^* mutants are solely due to the loss of NKX2-1 or also due to the subsequent gain of SOX2. Thus, we devised a genetic strategy to uncouple NKX2-1 and SOX2 regulation of tracheal and esophageal genes by generating *Nkx2-1; Sox2* compound mutant embryos. To achieve this, we again utilized *Nkx2.5-cre* to generate *Nkx2-1^lox/lox^; Nkx2.5^cre/+^* (Nkx2-1-TrKO) embryos lacking NKX2-1, and *Nkx2-1^lox/lox^; Sox2^lox/lox^; Nkx2.5^cre/+^* (Nkx2-1-TrKO; Sox2-TrKO) embryos lacking both NKX2-1 and SOX2 in the ventral foregut/trachea cells ([Figure 5a--c](#fig5){ref-type="fig"}). Similar to the Nkx2-1-TrKO embryos, all Nkx2-1-TrKO; Sox2-TrKO embryos we examined exhibited a complete failure of foregut separation (n = 6/6 embryos). We then examined NKX2-1-regulated genes that were determined by our scRNA-seq analysis to be markers of E11.5 trachea or esophagus. The expression of the tracheal-specific genes *Pcdh10* and *Tppp3* was decreased in Nkx2-1-TrKO and Nkx2-1-TrKO; Sox2-TrKO ventral foreguts indicating that their expression requires NKX2-1 but not upregulation of SOX2 ([Figure 5d--i'](#fig5){ref-type="fig"}), Conversely, expression of the esophageal-specific genes *Klf5* and *Has2* was upregulated in the ventral foreguts of Nkx2-1-TrKO, as predicted from our RNA-seq analysis ([Figure 5j--o'](#fig5){ref-type="fig"}). Interestingly, whereas *Klf5* expression was also increased in the ventral foregut of Nkx2-1^tr/tr^; Sox2^tr/tr^ mutants (arrowhead [Figure 5l,l'](#fig5){ref-type="fig"}), *Has2* expression was not, with the exception of a few cells that retain SOX2 expression ventrally (arrowhead in [Figure 5o,o'](#fig5){ref-type="fig"}). Thus, while *Klf5* and *Has2* were both repressed by NKX2-1, upregulation of *Has2* in the ventral foregut of Nkx2-1-TrKO embryos appears to also depend on the upregulation of SOX2 in this region. Together, these results revealed that NKX2-1 regulation results from both direct activation of tracheal genes and repression of esophageal genes, as well as the indirect suppression of target genes through the repression of *Sox2*, illustrating the complex relationship between these two transcription factors with opposing expression patterns.

![NKX2-1 regulates target genes in a SOX2-dependent and independent manner.\
(**a-c**) Schematic of *Nkx2-1; Sox2* compound mutant analysis phenotypes and resulting NKX2-1 and SOX2 expression patterns in E11.5 control embryos (**a**), Nkx2-1-TrKO mutants (**b**), Nkx2-1-TrKO; Sox2-TrKO mutants (**c**). 8/8 Nkx2-1-TrKO embryos and 6/6 Nkx2-1-TrKO; Sox2-TrKO embryos examined had TEF phenotype. (**d-f**) RNA localization of NKX2-1-dependent, SOX2-independent gene *Pcdh10* in control (**d**), Nkx2-1-TrKO (**e**), and Nkx2-1-TrKO; Sox2-TrKO (**f**) embryos with immunofluorescent staining of NKX2-1 (magenta) and SOX2 (cyan). (**g--i**) Tracheal, NKX2-1-dependent, SOX2-independent gene *Tppp3*. (**j--l**) Esophageal, NKX2-1-dependent, SOX2-independent gene *Klf5*. Solid arrowheads indicate SOX2-negative, *Klf5*-positive ventral cell. (**m--o**) Esophageal, NKX2-1-dependent, SOX2-dependent gene *Has2*. Arrowheads indicate ventral SOX2-positive, *Has2*-positive cells. n = 3 embryos/staining combination. All images were captured at 20X magnification and displayed at the same scale. Scale = 50 um.](elife-55526-fig5){#fig5}

NKX2-1 regulates *Wnt7b* and *Shh* to couple tracheal endoderm identity to mesenchymal cell fate {#s2-4}
------------------------------------------------------------------------------------------------

The apparent fate transformation of *Nkx2-1^-/-^* mutant trachea to esophagus is supported by the conversion of ventral mesenchymal cell fates from tracheal cartilage to smooth muscle ([@bib29]; [@bib40]; [@bib62]). We confirmed previous reports of a dramatic reduction and disorganization of tracheal cartilage with expansion of the smooth muscle in *Nkx2-1^-/-^* mutants, and additionally observed malformation of the thyroid and cricoid cartilage (n = 3/3 embryos, [Figure 6a,o,p](#fig6){ref-type="fig"}). Our finding that the endoderm in *Nkx2-1^-/-^* mutants did not exhibit a complete fate transformation led us to ask whether we could uncover the specific NKX2-1 targets that impact epithelial to mesenchymal signaling amongst this more limited set of candidates. Notably, *Wnt7b* expression decreased and *Shh* increased in *Nkx2-1^-/-^* foregut epithelium compared to WT ([Figure 2a](#fig2){ref-type="fig"}), and both signaling genes have known functions in tracheal cartilage and smooth muscle formation. In WT E11.5 and E13.5 embryos, *Wnt7b* is expressed in the tracheal epithelium and *Shh* is expressed more strongly in the esophageal epithelium ([@bib6]; [@bib22]; [@bib41]; [@bib50]; [Figure 6c,f,i,m](#fig6){ref-type="fig"}). We examined our NKX2-1 ChIP-seq data to determine whether NKX2-1 binds directly to *Wnt7b* and *Shh* in the trachea and observed binding at three sites 20 kb and 60 kb upstream and 20 kb downstream of the *Wnt7b* gene. Though a previous study detected binding of NKX2-1 to the *Wnt7b* promoter in a lung epithelial cell line ([@bib61]), we instead observe binding at three sites 20 kb and 60 kb upstream and 20 kb downstream of the *Wnt7b* gene. We also observed two NKX2-1 ChIP-seq peaks within the *Shh* gene, and two additional peaks 50 kb and 150 kb upstream of *Shh*, consistent with the possibility of direct regulation by NKX2-1 ([Figure 6b](#fig6){ref-type="fig"}). Together, these data indicate that *Wnt7b* and *Shh* are targets of NKX2-1 regulation in the developing foregut.

![NKX2-1 regulates mesenchymal specification via *Wnt7b* and *Shh*-mediated epithelial-mesenchymal crosstalk.\
(**a**) Alcian blue staining of tracheal cartilage in E18.5 control and *Nkx2-1^-/-^* embryos. 3/3 embryos examined exhibited similar cartilage phenotype. (**b**) ChIP-seq of direct NKX2-1 binding near *Wnt7b* and *Shh* loci. Input and NKX2-1 IP tracks are displayed at the same linear scale, as indicated by IGV Data Range on the y-axis. Horizontal scale bar = 10 kb. (**c--h**) RNA localization (green) of *Wnt7b* (**c--e**) and *Shh* (**f--h**) in control (left), Nkx2-1-TrKO (middle), and Nkx2-1-TrKO; Sox2-TrKO (right) E11.5 embryos with immunofluorescent staining of NKX2-1 (magenta) and SOX2 (cyan). (**i--j**) RNA localization of *Wnt7b* (red) and *Axin2* (yellow) in WT and *Nkx2-1^-/-^* E13.5 foreguts. 3/3 embryos display phenotype. (**k--l**) SOX9 staining (green) of cartilage progenitors in WT and *Nkx2-1^-/-^* E13.5 foreguts. 3/3 embryos display phenotype. (**m--n**) RNA localization of *Shh* (red) and *Ptch1* (yellow) in WT and *Nkx2-1^-/-^* E13.5 foreguts. 2/2 embryos display phenotype. (**o--p**) Smooth muscle actin (SMA) staining (cyan) of smooth muscle in WT and *Nkx2-1^-/-^* E13.5 foreguts. 3/3 embryos display phenotype. All images were captured at 20X magnification and images within each staining panel are at the same scale. Scale = 50 um.](elife-55526-fig6){#fig6}

To determine whether NKX2-1 regulates *Wnt7b* and *Shh* through a change in SOX2 expression, we examined *Nkx2-1; Sox2* compound mutants. *Wnt7b* expression was lost in both Nkx2-1-TrKO and Nkx2-1-TrKO; Sox2-TrKO foreguts, suggesting that NKX2-1 regulates *Wnt7b* independently of regulation by SOX2 ([Figure 6c--e'](#fig6){ref-type="fig"}). However, the increase in *Shh* expression in the ventral foregut observed in Nkx2-1-TrKO embryos was not observed in Nkx2-1-TrKO; Sox2-TrKO foreguts ([Figure 6f--h'](#fig6){ref-type="fig"}), indicating that SOX2 is required for upregulation of *Shh* in the ventral foregut. Thus, *Wnt7b* expression is positively regulated by NKX2-1 but not subject to regulation by SOX2, whereas the dorsally restricted expression of *Shh* is mediated by the combined action of NKX2-1 and SOX2.

To determine whether NKX2-1 regulation of *Wnt7b* and *Shh* impacts epithelial-mesenchymal signaling, we first examined the expression of *Wnt7b* and downstream canonical WNT signaling transcriptional target *Axin2* in E11.5 and E13.5 *Nkx2-1^-/-^* and WT foreguts. Whereas in WT embryos *Axin2* expression was localized to the ventral tracheal mesenchyme where SOX9+ cartilage progenitor cells are found, in *Nkx2-1^-/-^* mutants *Axin2* expression was decreased and correlated with disorganized SOX9 expression ([Figure 6i--l](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1a](#fig6s1){ref-type="fig"}). This decrease in *Axin2* expression was more dramatic in the caudal foregut, consistent with the increased severity of cartilage specification defects in this region seen in skeletal preparations ([Figure 6a](#fig6){ref-type="fig"}) and as visualized by SOX9 localization in *Nkx2-1^-/-^* foreguts ([Figure 6---figure supplement 1c--e](#fig6s1){ref-type="fig"}). We next examined the expression of *Shh* and downstream transcriptional target *Ptch1* in *Nkx2-1^-/-^* mutant and WT foreguts. In E11.5 and E13.5 *Nkx2-1^-/-^* foreguts, increased expression of *Shh* in the ventral foregut epithelium compared to WT was mirrored by an increase in *Ptch1* expression in the surrounding mesenchyme ([Figure 6m,n](#fig6){ref-type="fig"}; [Figure 6---figure supplement 1b](#fig6s1){ref-type="fig"}). This increase in *Ptch1* expression also corresponded with the increase in smooth muscle as visualized by ACTA2 (i.e. α-SMA) surrounding *Nkx2-1^-/-^* foreguts compared to WT ([Figure 6m--p](#fig6){ref-type="fig"}, S8c,f,g). Thus, our data show that in addition to regulating a subset of genes that define tracheoesophageal epithelial identity at this stage, NKX2-1 and SOX2 regulate epithelial-mesenchymal crosstalk via WNT and SHH signaling to instruct mesenchymal differentiation, explaining this aspect of the observed TE fate transformation in *Nkx2-1^-/-^* mutant foreguts ([Figure 7](#fig7){ref-type="fig"}).

![Proposed model of NKX2-1-dependent and -independent tracheoesophageal specification.\
(**a**) Schematic of NKX2-1 and SOX2 regulation of gene expression in WT trachea and esophagus, and epithelial-mesenchymal signaling downstream of NKX2-1. NKX2-1 negatively regulates esophageal genes *Shh, Klf5* and *Has2,* and positively regulates tracheal genes *Wnt7b, Tppp3,* and *Pcdh10.* SOX2 is required for expression of *Shh* and *Has2*. NKX2-1 regulation of *Shh* and *Wnt7b* influences mesenchymal SHH and WNT response required for smooth muscle and tracheal cartilage development. (**b**) Schematic of *Nkx2-1^-/-^* mutant phenotype. Maintenance of the NKX2-1-independent transcriptional program includes dorsal expression of *Dcn, Ackr3, Meis2, Pitx1,* and *Lrig1* and ventral expression of *Irx2, Ly6h,* and *Nrp2*. NKX2-1-dependent transcriptional changes include increased expression of esophageal genes and decreased expression of tracheal genes in the ventral foregut, accompanied by changes in epithelial-mesenchymal signaling and mesenchymal differentiation.](elife-55526-fig7){#fig7}

Discussion {#s3}
==========

NKX2-1 is a critical regulator of respiratory development across vertebrates ([@bib29]; [@bib43]; [@bib49]; [@bib62]), but how it directs TE specification was unknown. It has been previously demonstrated in adenocarcinoma and in the adult distal lung, that loss of NKX2-1 leads to adoption of a gastric transcriptional phenotype ([@bib23]; [@bib51]). Further, mesenchymal cues that induce lung and trachea development converge to establish ventral NKX2-1 expression, and *Nkx2-1^-/-^* mutant embryos exhibit dramatic epithelial and mesenchymal phenotypes. Together, these findings have led to the proposal that NKX2-1 is a master regulator of initial tracheal fate specification ([@bib2]; [@bib4]; [@bib7]; [@bib9]; [@bib32]; [@bib40]). By performing scRNA-seq profiling on the endoderm at the onset of tracheal and esophageal development, and comparing this profile to *Nkx2-1^-/-^* mutant embryos, we find that NKX2-1 loss does not cause a transcriptome-wide tracheal-to-esophageal conversion, but rather results in changes in expression of a key subset of dorsoventrally restricted genes that can explain apparent fate-conversion phenotypes in the mesenchyme ([Figure 7](#fig7){ref-type="fig"}).

The functional significance of the NKX2-1-independent tracheal program, and how it is established, remains to be explored. It is possible that mesenchymal signals such as WNT and BMP induce other tracheal transcriptional regulators in parallel. Interestingly, the ISL1 transcription factor has been recently identified to exhibit ventrally-restricted expression in the trachea and is required for normal NKX2-1 expression ([@bib15]). Further, our data reveal that *Isl1* is independent of NKX2-1 ([Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}), indicating that it resides hierarchically upstream of NKX2-1. It remains to be determined, however, the extent to which ISL1 regulates tracheal transcriptional identity. Our profiling of tracheoesophageal specification, combined with genomic analyses of additional mouse mutants, provide an exciting opportunity for further exploration of additional regulators of tracheoesophageal specification within the foregut epithelium.

Our scRNA-seq profiling reveals many new markers of dorsoventral foregut identity beyond *Nkx2-1* and *Sox2*. This of particular importance for human iPSC/ESC-derived models where *Nkx2-1* and *Sox2* expression are often used to indicate respiratory or esophageal/gut fate decisions ([@bib5]; [@bib10]; [@bib58]; [@bib64]). Our data suggest that in addition to using *Nkx2-1* as a marker of respiratory fate, differentiation protocols might be more thoroughly characterized using a panel of NKX2-1-dependent and -independent respiratory markers. Further, though we have not explored it in depth, we also provide here the first scRNA-seq dataset characterizing the lung at early stages of branching morphogenesis, which may additionally aid in more precise characterization of early lung development. Our study therefore provides a rich resource for expanding our understanding of early cell fate decisions in stem cell models of human foregut and lung development.

By defining the NKX2-1-dependent transcriptomic profile, we elucidate how NKX2-1 regulates initial tracheal and esophageal development at the genome-wide level. A dual repressive genetic relationship with SOX2 has been previously demonstrated, and our ChIP-seq data support direct repression of *Sox2* by NKX2-1. We find, however, that direct binding of NKX2--1 occurs more often at genes that are normally expressed in the trachea, and loss of tracheal gene expression in *Nkx2-1^-/-^* mutants is not indirectly mediated by upregulation of SOX2. Together, these findings broadly support a model in which NKX2-1 more often positively regulates the tracheal gene expression program directly. While we demonstrate that SOX2 is a mediator of NKX2-1-indirect regulation of some genes, SOX2 targets in the foregut have not been identified at the transciptomic level, and it is therefore unclear the extent to which SOX2 controls TE fates. Additionally, our identification of other NKX2-1-dependent transcription factors such as KLF5 provides candidates potentially mediating NKX2-1 indirect repression of esophageal genes.

Tracheal cartilage and smooth muscle phenotypes in *Nkx2-1^-/-^* embryos support a TE fate conversion phenotype ([@bib29]; [@bib40]); here we provide a likely explanation of these phenotypes and reveal how NKX2-1 may regulate development of the tracheal cartilage and restrict smooth muscle formation. Normal tracheal cartilage specification requires WNT signaling from the tracheal epithelium to the mesenchyme ([@bib12]; [@bib16]; [@bib50]). We find that NKX2-1 positively regulates *Wnt7b* resulting in activation of a canonical WNT-signaling response in the adjacent ventral tracheal mesenchyme. A recent report suggested that epithelial-mesenchymal WNT signaling during cartilage specification occurs through NKX2-1-independent mechanisms ([@bib16]). Our results differ from this finding but do support the possibility that an NKX2-1 independent mechanism also contributes to tracheal cartilage specification, as some disorganized cartilage still forms in *Nkx2-1^-/-^* mutants.

In addition to regulating WNT signaling, we found that NKX2-1 loss resulted in upregulation of *Shh* and increased SHH signal reception in the ventral mesenchyme. As HH signaling is a key regulator of smooth muscle formation in multiple contexts, and its disruption also results in perturbation of tracheal cartilage formation ([@bib13]; [@bib25]; [@bib28]; [@bib45]), it is likely that this upregulation also contributes to disruption of tracheal cartilage and expansion of smooth muscle formation. Notably, similar to the other trachea and esophagus markers we examined, NKX2-1 regulation of *Wnt7b* does not depend on SOX2, whereas the upregulation of *Shh* in *Nkx2-1^-/-^* mutants does. This fits with the broader model of NKX2-1 directly activating a defined tracheal program, but more often repressing an esophageal program through ventral repression of SOX2.

While few genetic causes of foregut anomalies in humans have been identified, human stem cell models have indicated that key players in respiratory and gut specification are conserved between mice and humans ([@bib36]; [@bib58]). Therefore, future work to understand genetic causes of foregut malformations in humans including tracheoesophageal fistula (TEF), tracheal agenesis, esophageal atresia, tracheomalacia, and tracheal stenosis will benefit greatly from the improved understanding of normal tracheal and esophageal specification presented in this study. Together, these findings dramatically advance our understanding of the earliest stages of tracheoesophageal development, while revising our perspective on the role of NKX2-1 in this process.

Materials and methods {#s4}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                       Designation                              Source or reference         Identifiers                              Additional\
  (species) or resource                                                                                                                             information
  ----------------------------------- ---------------------------------------- --------------------------- ---------------------------------------- -------------------------------------------
  Strain, strain background (mouse)   CD1                                      Harlan/Envigo               Cat\#: 030                               

  Genetic reagent (mouse)             Nkx2-1^fl/fl^                            [@bib18]                    MGI: 3653645                             

  Genetic reagent (mouse)             Sox2^fl/fl^                              [@bib46]                    MGI: 4366453                             

  Genetic reagent (mouse)             Tmem163^Tg^(Actin^cre^)                  [@bib20]                    MGI: 2176050                             

  Genetic reagent (mouse)             Nkx2.5cre                                [@bib52]                    MGI: 2448972                             

  Antibody                            α-NKX2-1 (rabbit polyconal)              Millipore                   Cat\#: 07601                             1:200 for IF, 5ug for ChIP

  Antibody                            α-SOX2 (goat polyclonal)                 Neuromics                   Cat\#: GT15098                           1:250 for IF

  Antibody                            α-SOX9 (Rabbit polyclonal)               Santa Cruz                  Cat\#: sc-20095                          1:250 for IF

  Antibody                            α-PITX1 (Rabbit polyclonal)              NovusBio                    Cat: NBP188644                           1:200 for IF

  Antibody                            α-LRIG1 (Goat polyclonal)                R&D Systems                 Cat\#: AF3688                            1:250 for IF

  Antibody                            α-SMA (Rabbit polyclonal)                Abcam                       AB5694                                   1:300 for IF

  Antibody                            α-SMA-cy3 (mouse monoclonal)             Sigma                       C6198                                    1:300 for IF

  Antibody                            α-EpCAM (rat polyclonal)                 BioLegend                   Cat\#: 118219                            1:200 for FACS

  Sequence-based reagent              RNAscope probe *mm-Irx2*                 Advanced Cell Diagnostics   Cat\#: 519901                            

  Sequence-based reagent              RNAscope probe *mm-Wnt7b*                Advanced Cell Diagnostics   Cat\#: 401131                            

  Sequence-based reagent              RNAscope probe *mm-Pcdh10*               Advanced Cell Diagnostics   Cat\#: 477781-C3                         

  Sequence-based reagent              RNAscope probe *mm-Tppp3*                Advanced Cell Diagnostics   Cat\#: 586631                            

  Sequence-based reagent              RNAscope probe *mm-Ly6h*                 Advanced Cell Diagnostics   Cat\#: 587811                            

  Sequence-based reagent              RNAscope probe *mm-Krt19*                Advanced Cell Diagnostics   Cat\#: 402941                            

  Sequence-based reagent              RNAscope probe *mm-Klf5*                 Advanced Cell Diagnostics   Cat\#: 444081                            

  Sequence-based reagent              RNAscope probe *mm-Foxe1*                Advanced Cell Diagnostics   Cat\#: 509641                            

  Sequence-based reagent              RNAscope probe *mm-Crabp1*               Advanced Cell Diagnostics   Cat\#: 474711-C3                         

  Sequence-based reagent              RNAscope probe *mm-Bmp4*                 Advanced Cell Diagnostics   Cat\#: 401301-C2                         

  Sequence-based reagent              RNAscope probe *mm-Nrp2*                 Advanced Cell Diagnostics   Cat\#: 500661                            

  Sequence-based reagent              RNAscope probe *mm-Dcn*                  Advanced Cell Diagnostics   Cat\#: 413281-C3                         

  Sequence-based reagent              RNAscope probe *mm-Has2*                 Advanced Cell Diagnostics   Cat\#: 465171-C2                         

  Sequence-based reagent              RNAscope probe *mm-Meis2*                Advanced Cell Diagnostics   Cat\#: 436371-C3                         

  Sequence-based reagent              RNAscope probe *mm-Ackr3*                Advanced Cell Diagnostics   Cat\#: 482561-C2                         

  Sequence-based reagent              RNAscope probe *mm-Axin2*                Advanced Cell Diagnostics   Cat\#: 400331-C3                         

  Sequence-based reagent              RNAscope probe *mm-Shh*                  Advanced Cell Diagnostics   Cat\#: 314361                            

  Sequence-based reagent              RNAscope probe *mm-Ptch1*                Advanced Cell Diagnostics   Cat\#: 402811-C2                         

  Sequence-based reagent              Nkx2-1-geno1                             This paper                  PCR primer                               5\'-CTA-GGG-AGG-CTA -GGA-ACT-CGG-3\'

  Sequence-based reagent              Nkx2-1-geno2                             This paper                  PCR primer                               5\'-CCG-ACC-CAC-GTA-GAG-CC-3\'

  Sequence-based reagent              Nkx2-1-geno3                             This paper                  PCR primer                               5\'-CTC-TTA-TCT-GGG-ATC-GCC-TGA-G-3\'

  Sequence-based reagent              Sox2-flox-geno1                          [@bib53]                    PCR primer                               5\'-TGG-AAT-CAG-GCT-GCC-GAG-AAT-CC-3\'

  Sequence-based reagent              Sox2-flox-geno2                          [@bib53]                    PCR primer                               5\'-TCG-TTG-TGG-CAA-CAA-GTG-CTA-AAG-C-3\'

  Sequence-based reagent              Sox2-flox-geno3                          [@bib53]                    PCR primer                               5\'-CTG-CCA-TAG-CCA-CTC-GAG-AAG-3\'

  Sequence-based reagent              Cre-geno1                                [@bib21]; [@bib59]          PCR primer                               5\'-GTT-CGC-AAG-AAC-CTG-ATG-GAC-A-3\'

  Sequence-based reagent              Cre-geno2                                [@bib21]; [@bib59]          PCR primer                               5\'-CTA-GAG-CCT-GTT-TTG-CAC-GTT-C-3\'

  Commercial assay or kit             MicroChIP Diapure columns                Diagenode                   Cat\#: C03040001                         DNA extraction (ChIP)

  Commercial assay or kit             Microplex Library Preparation Kit v2     Diagenode                   Cat\#: C05010012                         ChIP library prep

  Commercial assay or kit             Rneasy Micro kit                         Qiagen                      Cat\# 74004                              RNA extraction (bulk)

  Commercial assay or kit             SMARTer Stranded Total RNAseq kit V2     Takara                      Cat\#: 634411                            Bulk RNAseq library prep

  Commercial assay or kit             RNA 6000 Pico Bioanalyzer kit            Agilent                     Cat\# 5067-1513                          Bioanalyzer (RNA)

  Commercial assay or kit             High Sensitivity DNA Bioanalyzer kit     Agilent                     Cat\#: 5067-4626                         Bioanalyzer (DNA)

  Commercial assay or kit             QuBit dsDNA HS Assay kit                 Invitrogen                  Cat\#: Q32854                            DNA quantification

  Commercial assay or kit             Chromium Single Cell \' Reagent Kit V2   10X Genomics                Cat\#: PN-120237, PN-120236, PN-120262   Single cell RNA-seq

  Other                               Sytox Blue nuclei acid stain             Thermo                      Cat: S11348                              Live/dead stain for FACS, use at 1uM

  Other                               TSAplus Fluoresceine                     Akoya Biosciences           NEL741001KT                              RNAscope, 1:1500

  Other                               TSAplus Cy3                              Akoya Biosciences           NEL744001KT                              RNAscope, 1:1500

  Other                               TSAplus Cy5                              Akoya Biosciences           NEL745001KT                              RNAscope, 1:1500

  Other                               DynaBeads, protein G                     Invitrogen                  Cat\#: 10003D                            ChIP

  Other                               AMPure XP beads                          Beckman Coulter             Cat\#: A63881                            Library cleanup

  Other                               TrypLE Express                           Thermo                      Cat\# 12604013                           Tissue dissociation
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mice {#s4-1}
----

All animal procedures were performed at the University of California San Francisco (UCSF) under approval from the UCSF Institutional Animal Care and Use Committee (mouse protocol \# AN164190). Mouse embryos were collected from pregnant females via cesarean section at the described timepoint following observation of a vaginal plug. Noon the day of the plug was considered embryonic day 0.5. For single cell sequencing experiments, timed-pregnant CD1 female mice were obtained from Harlan/Envigo (Cat: 030) and embryos were staged using somite counts. For mutant analysis, the following alleles were used: *Nkx2-1^lox/lox^* (MGI: 3653645), *Sox2^lox/lox^* (MGI: 4366453), *Nkx2.5-Cre* (MGI: 2448972), Actin-Cre (MGI: 2176050).

Immunofluorescence {#s4-2}
------------------

Mouse embryos were dissected at E10.5 or E11.5 in cold PBS and fixed overnight in 4% paraformaldehyde at 4C. For cryopreservation, embryos were subjected to a sucrose gradient of 12.5% sucrose in PBS for 8 hr, followed by 25% sucrose in PBS overnight at 4°C, and embedded in OCT. Tissue sections of 12 um were cut using a cryostat and used for immunofluorescence, or in-situ hybridization followed by immunofluorescence with standard protocols. Primary antibodies used for immunofluorescence were: NKX2-1 (Millipore 07601, 1:200), SOX2 (Neuromics GT15098, 1:250), SOX9 (Santa Cruz, sc-20095, 1:250), LRIG1 (R&D, AF3688, 1:200), PITX1 (NovusBio, NBP188644, 1:250).

In-situ hybridization {#s4-3}
---------------------

For in-situ hybridization, 12 µm cryosections were stained using the RNAscope Multiplex Fluorescent Reagent Kit v2 (Advanced Cell Diagnostics, cat\# 323100) with the following adjustments to the manufacturer's protocol: antigen retrieval step was bypassed, protease step used ProteasePlus for 10 min. Following in-situ hybridization, slides were washed 2x in PBS and subjected to immunofluorescent staining as described in 'Immunofluorescence' above. Probes used for in-situ hybridization against mouse RNA were obtained from Advanced Cell Diagnostics as follows: *Irx2* (519901), *Wnt7b* (401131), *Pcdh10* (477781-C3), *Tppp3* (586631), *Ly6h* (587811), *Krt19* (402941), *Klf5* (444081), *Foxe1* (509641), *Crabp1* (474711-C3), *Bmp4* (401301-C2), *Nrp2* (500661), *Dcn* (413281-C3), *Has2* (465171-C2), *Meis2* (436371-C3), *Ackr3* (482561-C2), *Axin2* (400331-C3), *Shh* (314361), *Ptch1* (402811-C2).

Skeletal preparation {#s4-4}
--------------------

Skeletal preps were performed as previously described ([@bib26]).

Dissociation and FACS of embryonic tissue {#s4-5}
-----------------------------------------

Foregut tissue was dissected in cold PBS and dissociated to single cells using TrypLE Express (phenol-red free, Thermo cat\# 12604013) at 37°C for 5 min, followed by trituration for 1--3 min at 37°C. Cells were washed twice with FACS buffer (2 mM EDTA and 5% fetal bovine serum in phenol-red free HBSS). To identify epithelial cells, cells were stained with PerCP/Cy5.5 anti-mouse CD326/EpCAM (BioLegend, cat\# 118219, used at 1:100) at 4°C for 30 min followed by two washes with FACS buffer. Cells were resuspended in FACS buffer with Sytox Blue nucleic acid stain (Thermo, S11348, used at 1 µM) to stain dead cells, and passed through a 35 µm cell strainer. Cells were sorted using a BD FACS Aria II. Single live epithelial cells were collected after size selection and gating for Sytox-negative, EpCAM-positive cells. For scRNA-seq, cells were sorted into EDTA-free FACS buffer and processed as described below. For bulk-RNA-seq, cells were sorted directly into RNA lysis buffer (Qiagen RNeasy Micro kit, cat\# 74004) with 1% beta-mercaptoethanol and processed as described below.

Single-cell RNA sequencing {#s4-6}
--------------------------

Foregut tissue was dissected from 20 embryos at E10.5 (6-9ts) and 28 embryos at E11.5 (16-20ts). To ensure for representation of tracheal and esophageal cells at E11.5, lung tissue was separated from E11.5 foreguts and processed in parallel. Tissue from each timepoint was pooled and single-cell suspension and epithelial purification was performed as described above. 25,000 live epithelial cells from each sample were loaded into individual wells for single-cell capture using the Chromium Single Cell 3' Reagent Kit V2 (10X Genomics). Library preparation for each sample was also performed using the Chromium Single Cell 3' Reagent Kit V2, and each sample was given a unique i7 index. Libraries were pooled and subjected to sequencing in a single lane of an Illumina NovaSeq6000. Sequencing data were processed, and downstream analysis performed as described below.

RNA sequencing {#s4-7}
--------------

For bulk RNA-sequencing experiments, whole foregut tissue was dissected from E11.5 *Nkx2-1^-/-^* or WT embryos, and lungs were removed at the time of dissection. For RNA-sequencing of wild type (WT) trachea and esophagus, trachea and esophagus were manually separated at the time of dissection. Foreguts of individual embryos were dissociated, stained, and sorted as described above. Each biological replicate consisted of RNA pooled from two *Nkx2-1^-/-^* or WT embryos, with a total of 3 biological replicates from different litters. RNA was purified using the RNeasy Micro kit (Qiagen, cat\# 74004) and quantification was performed using the RNA 6000 Pico kit (Agilent, cat\# 5067--1513) on an Agilent 2100 Bioanalyzer. RNA-sequencing libraries were prepared from 4 ng of input RNA using the SMARTer Stranded Total RNAseq kit V2 (Takara, cat\# 634411) with 13 amplification cycles. Library size and quality was checked using an Agilent 2100 Bioanalyzer with the High Sensitivity DNA kit (Agilent, cat\# 5067--4626), and library concentration was determined with the QuBit dsDNA HS Assay kit (Invitrogen, cat\# Q32854). Libraries were normalized to 7 nM, pooled, and sequenced across two lanes of an Illumina HiSeq 4000 to generate 50 base pair single-end reads. Data processing and downstream analysis was performed as described below.

Chromatin immunoprecipitation and sequencing {#s4-8}
--------------------------------------------

For ChIP-seq experiments, tracheas were dissected from WT E11.5 mouse embryos and cross-linked with 1% cold PFA for 9 min. Crosslinking was stopped with glycine for a final concentration of 0.125M. The crosslinked tissue was washed 2x in PBS and stored at −80°C. For each replicate 175 trachea were pooled and the tissue was thawed and dissociated in cold PBS by passing through a 25G needle until fully dissociated. The cells were lysed in 500 µl lysis buffer (50 mM Tris-HCl pH8, 2 mM EDTA pH8, 0.1% NP-40, 10% glycerol in DNase/RNase-free water) with protease inhibitors (Aprotinin, Pepstatin A, Leupeptin, 1 mM PMSF) for 5 min on ice. Nuclei were pelleted by spinning cells at 845xg for 5 min at 8°C, then lysed with 500 µl SDS lysis buffer (50 mM Tris-HCl + 10 mM EDTA + 1% SDS in sterile water) for 5 min on ice. The chromatin from lysed nuclei in SDS lysis buffer was sheared to obtain 200--500 bp DNA fragments using a Diagenode Bioruptor with 35 cycles (30 s on/off) submerged in cold water. Fragment sizes were determined by running a 20 µl aliquot of reverse-crosslinked chromatin on a 1.5% agarose gel. The sheared chromatin was diluted 1:10 with ChIP dilution buffer (50 mM Tris-HCl, 2 mM EDTA, 0.5M NaCl, 0.1% SDS in sterile water) then pre-cleared with washed Dynabeads Protein G for 1 hr at 4°C. The Dynabeads were magnetically isolated from chromatin and 1% of chromatin was separated and reverse crosslinked to be used as input. The remaining sample was incubated with Nkx2-1 antibody (Millipore 07601) overnight at 4°C. To isolate antibody-bound DNA, washed Dynabeads Protein G were added to each sample (50 ul beads/sample) and incubated for 30 min at 4°C.The Dynabeads with antibody-bound chromatin were isolated magnetically and subjected to 3x washes each with wash buffer (10 mM Tris-HCl, 2 mM EDTA, 0.5M NaCl, 0.1% SDS, 1% NP-40 in sterile water), LiCl buffer (10 mM Tris-HCl, 2 mM EDTA, 0.5M LiCl, 0.1% SDS, 1% NP-40), and TE buffer (1 mM Tris-HCl, 1 mM EDTA) for 5 min on ice. The chromatin was eluted in 100 µl of 2% SDS in TE on a 65°C heatblock with vigorous shaking (1400 rpm) for 15 min. Input DNA and immunoprecipitated DNA were reverse crosslinked by adding 5 µl 5M NaCl to 100 µl eluate and incubating overnight at 65°C, followed by a 30 min treatment with RNase. The reverse crosslinked DNA was purified using MicroChIP Diapure columns (Diagenode, cat\# C03040001) and eluted in 10 µl of elution buffer. The entire eluate of Nkx2-1 immunoprecipitated DNA and 0.5 ng of input DNA were used to prepare ChIP libraries. The libraries were prepared using the Microplex Library Preparation Kit v2 (Diagenode, cat\# C05010012) according to manufacturer\'s instructions with 14 amplification cycles. Library quality and size were calculated using an Agilent 2100 Bioanalyzer with the High Sensitivity DNA kit (Agilent, cat\# 5067--4626), and library concentration was quantified with the QuBit dsDNA HS Assay kit (Invitrogen, cat\# Q32854). The libraries were pooled to 5 nM and sequenced in one lane of an Illumina HiSeq 4000. The sequencing data were processed and downstream analysis was performed as described below.

Analysis of scRNA-seq data {#s4-9}
--------------------------

We used the Cell Ranger v2.1.1 pipeline from 10X Genomics for initial processing of raw sequencing reads. Briefly, raw sequencing reads were demultiplexed, aligned to the mouse genome (mm10), filtered for quality using default parameters, and UMI counts were calculated for each gene per cell. Filtered gene-barcode matrices were then analyzed using the Seurat v3.0 R package ([@bib55]). Seurat objects were generated with CreateSuratObject (min.cells = 10, min.features = 200) for E10.5 foregut and lung cells, E11.5 foregut cells, and E11.5 lung cells. E11.5 foregut and lung cells were merged to create a single gene-barcode matrix. Cells were further filtered based on the distribution of number of genes (nFeature) and percent mitochondrial genes (percent.mito) per cell across the dataset as follows. nFeature_RNA (E10.5):\>2000,\<7000, nFeature_RNA (E11.5):\>2500,\<8500, percent.mito:\>0.5,\<7.5. Data were normalized for sequencing depth, log-transformed, and multiplied by a scale factor of 10000 using the default parameters of NormalizeData. Linear regression was performed to eliminate variability across cell cycle stage (CellCycleScoring) and mitochondrial content using ScaleData. For E11.5 merged foregut and lung, nCount_RNA was also regressed out as these datasets retained slight variability in sequence depth that was not eliminated with ScaleData. The top 2000 variable genes within each dataset were selected based on a variance stabilizing transformation (FindVariableGenes, selection.method = 'vst') and used in downstream principal component analysis (PCA). The principal components (PCs) were identified with RunPCA and PCs to include in downstream analysis were empirically determined with visualization of PCs in an ElbowPlot. Cell clusters were identified by construction of a shared nearest neighbor graph (FindNeighbors) and a modularity optimization-based clustering algorithm (FindClusters) using the PCs determined by PCA (E10.5 dims = 1:20, E11.5 dims = 1:12). Clustering was performed at multiple resolutions between 0.2 and 2, and optimal resolution was determined empirically based on the expression of known population markers and the FindMarkers function (E10.5 resolution = 0.55, E11.5 resolution = 0.45). Several outlying clusters of mesenchymal contamination were removed, and cells were re-clustered for visualization purposes. Cells and clustering were visualized using Uniform Manifold Approximation and Projection (UMAP) dimensional reduction (RunUMAP). Markers for each cluster were identified with FindAllMarkers using default parameters, and cluster identity was determined based on the presence of known markers, as well as experimental evidence of RNA localization in specific cell types.

Analysis of bulk RNA-seq data {#s4-10}
-----------------------------

Analysis of RNA-seq reads was performed as described previously ([@bib38]). Differential expression analysis (*Nkx2-1^-/-^* vs WT, WT trachea vs WT esophagus) was performed using DESeq2 ([@bib24]) (test = c('Wald'), betaPrior = T) and genes with a log2 fold change \> 0.7 or\<−0.7 and an adjusted p-value\<0.05 were determined to be differentially expressed. Differential expression results were visualized using the ggplot2 package.

Analysis of ChIP-seq data {#s4-11}
-------------------------

FASTQ files of raw sequencing reads for NKX2-1 ChIP and input libraries were processed using a custom script ([github.com/akelakuwahara/foregut/run ChIPseq](https://github.com/mpercharde/ChIPseq)). Quality and length trimming and generation of fastqc files to examine sequence quality were performed using Trim Galore ([@bib17]). Trimmed reads were aligned to the mouse genome (mm9) using bowtie2 and sorted deduplicated bam files were generated using samtools. Peak calling was performed with MACS2 ([@bib63]) using a false discovery rate less than 1e-5 (macs2 callpeak -t chip.sorted.bam -c input.sorted.bam -f BAM -q 0.00001 g mm -n nkx_peaks `--outdir` macs/). Peaks shared between both replicates were identified by finding the intersection of both replicates using the Intersect tool in Galaxy ([usegalaxy.org](https://usegalaxy.org/)). Motif analysis to test for the enrichment of the NKX2-1 motif was performed with MEME ChIP using a 500 bp region flanking the peak summit for all peaks shared between both replicates. NKX2-1 binding at specific loci was visualized in the Integrative Genomics Viewer. Peak-gene associations were generated with GREAT using the basal-plus-extension rule ([@bib27]).

Code availability {#s4-12}
-----------------

All code used for data analysis is available at <https://github.com/akelakuwahara/foregut> ([@bib19]; copy archived at <https://github.com/elifesciences-publications/foregut>). 
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

This manuscript provides a significant amount of new information about how NKX2.1 and SOX2 act in concert to regulate the esophageal and tracheal developmental programs. A particular strength of the manuscript is the coupling of functional genetic experiments with the sequencing data.

**Decision letter after peer review:**

Thank you for submitting your article \"Delineating the early transcriptional specification of the mammalian trachea and esophagus\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Edward Morrisey as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, we are asking editors to accept without delay manuscripts, like yours, that they judge can stand as *eLife* papers without additional data, even if they feel that they would make the manuscript stronger. Thus, the revisions requested below only address clarity and presentation.

Summary:

This manuscript provides new information about how NKX2.1 and SOX2 act in concert to regulate the esophageal and tracheal developmental programs. Overall the manuscript is compelling in that the conclusions are well supported by strong single cell sequencing and mouse genetic experiments.

Revisions:

1\) Provide information on numbers for mouse genetic experiments. How many replicate embryos were examined, and how much heterogeneity in phenotype there is across embryos. It will be important to report how many embryos were examined in each case. It will also be helpful if some quantification of the phenotypes is presented -- i.e. what proportion of the embryos examined displayed a similar phenotype?

2\) Scale bars are generally not reported or lack units -- both of these will be helpful for the reader.

i.e. IF/FISH images lack scale bars. ChIP-seq data lack scale and are important for judging the size of peaks, especially between different genes, heatmaps (i.e. Figure 1C) have a scale bar, but units are not reported -- are these z-scores?

3\) Provide code for the analysis.
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Author response

> Revisions:
>
> 1\) Provide information on numbers for mouse genetic experiments. How many replicate embryos were examined, and how much heterogeneity in phenotype there is across embryos. It will be important to report how many embryos were examined in each case. It will also be helpful if some quantification of the phenotypes is presented -- i.e. what proportion of the embryos examined displayed a similar phenotype?

We have updated figure legends to reflect replicate numbers for each experiment and have added descriptions in the text of mutant phenotypes, which were fully penetrant in every genetic model.

> 2\) Scale bars are generally not reported or lack units -- both of these will be helpful for the reader.
>
> i.e. IF/FISH images lack scale bars. ChIP-seq data lack scale and are important for judging the size of peaks, especially between different genes, heatmaps (i.e. Figure 1C) have a scale bar, but units are not reported -- are these z-scores?

IF/FISH images: we have added units to the scale bar in each image panel, and have indicated in the figure legend that all images within an image panel are taken at the same magnification and displayed at the same scale.

ChIP data: We have included a scale bar indicating the horizontal scale (in kb) of each displayed track, as well as the IGV data range on the y-axis. We have also indicated within the figure legend that the data range for the input and NKX2.1 IP tracks displayed for each gene are scaled equivalently.

Heatmaps: We have included units (z-score) on all heatmaps (Figure 1C, Figure 1---figure supplement 2).

> 3\) Provide code for the analysis.

We have included a section of "Code availability" within the Materials and methods portion of the paper that includes a link to the Github page with the code files for analyses performed in this manuscript.
